Acadia Pharmaceuticals, a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, announced that it has extended its drug discovery and development collaboration with Allergan. 

The collaboration is focused on the discovery of innovative new therapeutics for glaucoma and other ophthalmic indications and was originally established in March 2003. The research term of this collaboration has now been extended for an additional year through March 2012. Acadia also has two other collaboration agreements with Allergan, which have led to current clinical programs in the areas of chronic pain and glaucoma.